Target cut to JPY 11,000 as Chugai Pharmaceutical stock trades at EUR 37.59

Published on 10/22/2026 at 09:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Simply Wall St says the target fell from JPY 12,440 to JPY 11,000 on October 18, 2026. Chugai Pharmaceutical stock costs EUR 37.59 on October 22, 2026.

Target and reporting date

Simply Wall St reported a target change from JPY 12,440 to JPY 11,000 on October 18, 2026.
Chugai's second-quarter 2026 revenue reached JPY 341.58 billion and net income reached JPY 116.33 billion.
Chugai Pharmaceutical stock was trading at EUR 37.59 at 9:41 a.m. CEST at Lang & Schwarz on October 22, 2026.
Chugai Pharmaceutical is scheduled to publish third-quarter 2026 results on October 27, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical stock was trading at EUR 37.59 at Lang & Schwarz on October 22, 2026, at 9:41 a.m. CEST. The latest analyst-related development was a target revision from JPY 12,440 to JPY 11,000, reported by Simply Wall St on October 18, 2026.

Target reset tests the valuation

The revision puts valuation discipline at the center of the Chugai story. The source described the lower target as a response to revised revenue-growth and margin assumptions alongside a lower future earnings multiple. That combination matters because it separates operating progress from the price investors are willing to pay for each unit of earnings.

Chugai remains listed on the Tokyo Stock Exchange under ticker 4519 and ISIN JP3519400000, according to Global Banking and Finance. The company operates as a pharmaceutical group with a strong research and development focus and a strategic alliance with Roche.

What do the latest results show?

For the second quarter of fiscal 2026, Chugai reported revenue of JPY 341.58 billion and net income of JPY 116.33 billion. JPX Market Explorer reported that quarterly revenue increased 17.8 percent from the comparable quarter, while net margin reached 34.1 percent versus 33.5 percent a year earlier. The figures give the target revision a concrete counterpoint: profitability improved even as the valuation framework became more cautious.

The company is scheduled to report third-quarter fiscal 2026 results on October 27, 2026, with the date listed on Chugai's investor-relations page. The release will show whether the earnings trend continued through the nine months ended September 2026.

Stock price and next result

The next company-specific test is the October 27 reporting date. Investors will be watching revenue growth, net income and the margin measure that shaped the latest target discussion.

Chugai Pharmaceutical stock was trading at EUR 37.59 at Lang & Schwarz on October 22, 2026, at 9:41 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.